Trifluoroacetic Acid
Trifluoroacetic acid is a corrosive organofluorine compound that is structurally analogous to, but stronger than, acetic acid. Available in various quantities and reagent grades, it is used in NMR spectroscopy, mass spectrometry, organic synthesis, etc.
Almost 100,000-fold more acidic than acetic acid, TFA is widely used in organic chemistry. TFA is used as a reagent in organic synthesis because of its properties: volatility, organic solvent solubility, and acidic strength. It is less oxidizing than sulfuric acid and is more readily available in its anhydrous form than some other acids . Other features include:
- Used in acid-catalyzed reactions, especially peptide synthesis (to cleave esters)
- Dissolves protein when mixed with liquid SO2
- Removes t-butyl derived side-chain protecting groups in Fmoc peptide synthesis
- Can remove the t-butoxycarbonyl protecting group in organic synthesis
- At low concentrations, acts as an ion-pairing agent for peptides and small proteins in organic compound liquid chromatography
- For acid-stable materials, can be a solvent for NMR spectroscopy
- Acts as a calibrant in mass spectrometry
- Used to produce trifluoroacetate salts
- An ingredient in adhesives, sealants, paints, and coatings
When TFA combines with bases and metals, especially light metals, a strong exothermic reaction occurs. When mixed with lithium aluminum hydride (LAH), the reaction is explosive.
Although nonflammable, TFA is corrosive to skin, eyes, and mucous membranes and requires careful use and handling. It is harmful when inhaled, causes severe skin burns and eye damage, and is toxic to aquatic organisms at even low concentrations.
TFA is also a product of the metabolic breakdown of the anesthetic agent halothane. It is the suspected cause of halothane-induced hepatitis.
Medchemexpress LLC GHRF, mouse TFA (mouse growth hormone-releasing factor TFA) | 98.9% | 5032.74 | 25 MG
GHRF, mouse TFA is a mouse growth hormone-releasing factor. It is a peptide composed of 44 amino acids. This substance stimulates the release and synthesis of growth hormone. It is intended for research use only and not for sale to patients.
- Appearance: white to off-white solid
- Stimulates release and synthesis of growth hormone
- Suitable for research use only
- Peptide sequence: His-Val-Asp-Ala-Ile-Phe-Thr-Thr-Asn-Tyr-Arg-Lys-Leu-Leu-Ser-Gln-Leu-Tyr-Ala-Arg-Lys-Val-Ile-Gln-Asp-Ile-Met-Asn-Lys-Gln-Gly-Glu-Arg-Ile-Gln-Glu-Gln-Arg-Ala-Arg-Leu-Ser
- Store sealed, away from moisture
- Powder storage: -80°C for 2 years; -20°C for 1 year
- In-solvent storage: -80°C for 6 months; -20°C for 1 month
- In vitro solubility in DMSO: 100 mg/mL (requires ultrasonic)
- Comprehensive documentation available
Medchemexpress LLC WDR5-IN-4 TFA | 2749300-35-2 | 98.0% | 612.40 | 1 ML
WDR5-IN-4 TFA (Compound C6) is an inhibitor of the WIN site of chromatin-associated WD repeat-containing protein 5 (WDR5), with a Kd of 0.1 nM. It displaces WDR5 from chromatin and decreases the expression of associated genes, leading to translational inhibition and nucleolar stress. This compound also exhibits anti-cancer activity.
- Inhibits the proliferation of MLL1-rearranged cancer cells MV4:11 and K562 cells with GI50s of 3.20 μM and 25.4 μM respectively, when treated with 0-50 μM for 3 days.
- Arrests the cell cycle of MV4:11 at the sub-G1 phase and induces apoptosis in MV4:11 when treated with 2 μM for 6 days.
- Promotes Hox genes in hindbrains of Rnf220+/- mice at late embryonic stages with an intrauterine injection of 100 μg (single dose).
Medchemexpress LLC Gln-AMS TFA | 209543-57-7 | >99.85% | 588.47 | 1 MG
Gln-AMS (TFA) is a type Ia aminoacyl-tRNA synthetase (AARS) inhibitor. It inhibits glutaminyl-tRNA synthetase (GlnRS) with a Ki of 1.32 μM. It is for research use only.
- Type Ia aminoacyl-tRNA synthetase (AARS) inhibitor
- Inhibits glutaminyl-tRNA synthetase (GlnRS) with a Ki of 1.32 μM
Medchemexpress LLC Hth-01-091 Tfa | 2000209-42-5 | 98.64% | 499.43 | 1 MG
HTH-01-091 is a potent and selective maternal embryonic leucine zipper kinase (MELK) inhibitor, with an IC50 of 10.5 nM. It also inhibits PIM1/2/3, RIPK2, DYRK3, smMLCK, and CLK2. This compound can be used for breast cancer research.
- Potent and selective MELK inhibitor.
- Inhibits multiple kinases including PIM1/2/3, RIPK2, DYRK3, smMLCK, and CLK2.
- Suitable for breast cancer research.
Medchemexpress LLC Gln-AMS TFA | 99.9% | 588.47 | 100 MG
Gln-AMS (TFA) is a type Ia aminoacyl-tRNA synthetase (AARS) inhibitor, specifically inhibiting glutaminyl-tRNA synthetase (GlnRS) with a Ki of 1.32 μM.
- Inhibits glutaminyl-tRNA synthetase (GlnRS)
- Type Ia aminoacyl-tRNA synthetase (AARS) inhibitor
- White to off-white solid
- Purity of 99.85%
- Soluble in DMSO at 100 mg/mL
- Store at -20°C under nitrogen
Medchemexpress LLC Adrixetinib (TFA) | 2394874-66-7 | C27H25F6N5O7 | 1 ML
Adrixetinib (TFA) is a protein tyrosine kinase (PTK) inhibitor (antagonist) with anti-tumor effects.
- Molecular formula: C27H25F6N5O7.
- Molecular weight: 645.51.
- Appearance: Off-white to light yellow solid.
- Purity (HPLC) of 99.82%.
- Recommended storage at 4°C in sealed conditions, away from moisture.
- When in solvent, store at -80°C for up to 6 months or -20°C for up to 1 month, under sealed conditions and away from moisture.
Medchemexpress LLC Jbsnf-000028 TFA | C13H14F3N3O2 | 5 MG
JBSNF-000028 TFA is an orally active small molecule inhibitor of the tricyclic nicotinamide N-methyltransferase (NNMT). It has demonstrated significant anti-obesity and anti-diabetic activities in diet-induced obesity models and is used for studying metabolic diseases such as obesity, type 2 diabetes, and non-alcoholic fatty liver disease.
- Orally active small molecule inhibitor of tricyclic nicotinamide N-methyltransferase (NNMT).
- Inhibits NNMT activity with an EC50 of 2.5 μM in U2OS cells.
- Shows no cytotoxicity against HepG2 cells at 10-100 μM.
- Improves glucose and lipid handling in mice with diet-induced obesity.
- Improves glucose tolerance in NNMT knockout mice with diet-induced obesity.
